An open label, prospective, observational, non-interventional study of intravenous epoprostenol (Veletri) in patients with severe pulmonary arterial hypertension
Latest Information Update: 07 Feb 2023
At a glance
- Drugs Epoprostenol (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- 07 Feb 2023 New trial record